Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30196% above fair value
$11.62+0.72 (+6.61%)
Close on Nov 13, 2026Market cap $407.48MP/E 387.3Yield –
Fennec Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Fennec Pharmaceuticals's cash was $48.68M at Sep 30, 2026. For fiscal 2025 it was $36.79M, up 38.1% from the year before. Over ten years it grew 44.3% a year on average. The highest annual figure on record is $678.00M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.79M | +38.1% |
| FY2024 | Dec 31, 2024 | $26.63M | +100.7% |
| FY2023 | Dec 31, 2023 | $13.27M | -44.2% |
| FY2022 | Dec 31, 2022 | $23.77M | +7644.0% |
| FY2021 | Dec 31, 2021 | $307.00K | +3737.5% |
| FY2020 | Dec 31, 2020 | $8.00K | -100.0% |
| FY2019 | Dec 31, 2019 | $678.00M | +2876.2% |
| FY2018 | Dec 31, 2018 | $22.78M | -19.4% |
| FY2017 | Dec 31, 2017 | $28.26M | +619.8% |
| FY2016 | Dec 31, 2016 | $3.93M | +316.8% |
| FY2015 | Dec 31, 2015 | $942.00K | -59.2% |
| FY2014 | Dec 31, 2014 | $2.31M | +38.7% |
| FY2013 | Dec 31, 2013 | $1.66M | -27.8% |
| FY2012 | Dec 31, 2012 | $2.30M | -56.5% |
| FY2011 | Dec 31, 2011 | $5.30M | -10.9% |
| FY2010 | Dec 31, 2010 | $5.95M | +768.2% |
| FY2009 | Dec 31, 2009 | $685.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $48.68M | +121.8% |
| Q2 FY2026 | Jun 30, 2026 | $41.25M | +120.5% |
| Q1 FY2026 | Mar 31, 2026 | $40.18M | +77.2% |
| Q4 FY2025 | Dec 31, 2025 | $36.79M | +38.1% |
| Q3 FY2025 | Sep 30, 2025 | $21.95M | -45.6% |
| Q2 FY2025 | Jun 30, 2025 | $18.71M | -56.6% |
| Q1 FY2025 | Mar 31, 2025 | $22.68M | -55.7% |
| Q4 FY2024 | Dec 31, 2024 | $26.63M | +100.7% |
| Q3 FY2024 | Sep 30, 2024 | $40.32M | +225.2% |
| Q2 FY2024 | Jun 30, 2024 | $43.05M | +187.8% |
| Q1 FY2024 | Mar 31, 2024 | $51.18M | +178.3% |
| Q4 FY2023 | Dec 31, 2023 | $13.27M | -44.2% |
| Q3 FY2023 | Sep 30, 2023 | $12.40M | -58.3% |
| Q2 FY2023 | Jun 30, 2023 | $14.96M | +0.3% |
| Q1 FY2023 | Mar 31, 2023 | $18.39M | +0.7% |
| Q4 FY2022 | Dec 31, 2022 | $23.77M | +7644.0% |
| Q3 FY2022 | Sep 30, 2022 | $29.75M | +22.3% |
| Q2 FY2022 | Jun 30, 2022 | $14.92M | -45.4% |
| Q1 FY2022 | Mar 31, 2022 | $18.26M | -31.7% |
| Q4 FY2021 | Dec 31, 2021 | $307.00K | +3737.5% |
| Q3 FY2021 | Sep 30, 2021 | $24.34M | -26.6% |
| Q2 FY2021 | Jun 30, 2021 | $27.29M | -29.5% |
| Q1 FY2021 | Mar 31, 2021 | $26.75M | +170.2% |
| Q4 FY2020 | Dec 31, 2020 | $8.00K | -100.0% |
| Q3 FY2020 | Sep 30, 2020 | $33.17M | +117.6% |
| Q2 FY2020 | Jun 30, 2020 | $38.73M | +183.7% |
| Q1 FY2020 | Mar 31, 2020 | $9.90M | -51.1% |
| Q4 FY2019 | Dec 31, 2019 | $678.00M | +2876.2% |
| Q3 FY2019 | Sep 30, 2019 | $15.24M | -37.9% |
| Q2 FY2019 | Jun 30, 2019 | $13.65M | -46.8% |
| Q1 FY2019 | Mar 31, 2019 | $20.23M | -24.3% |
| Q4 FY2018 | Dec 31, 2018 | $22.78M | -19.4% |
| Q3 FY2018 | Sep 30, 2018 | $24.52M | +153.1% |
| Q2 FY2018 | Jun 30, 2018 | $25.64M | +150.6% |
| Q1 FY2018 | Mar 31, 2018 | $26.72M | +721.9% |
| Q4 FY2017 | Dec 31, 2017 | $28.26M | +619.8% |
| Q3 FY2017 | Sep 30, 2017 | $9.69M | – |
| Q2 FY2017 | Jun 30, 2017 | $10.23M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.25M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.93M | – |
See a number that looks wrong?